메뉴 건너뛰기




Volumn 4, Issue 3, 2002, Pages 381-388

Clinical trials update: Highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL

Author keywords

AFFIRM; AZACS; BNP trial; CHRISTMAS; DANAMI 2; ENABLE 1 2; HARDBALL; LIFE; MADIT 2; MIRACLE ICD; OCTAVE; OVERTURE; RACE; REMATCH; WIZARD

Indexed keywords

ALTEPLASE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; LOSARTAN; OMAPATRILAT; PLACEBO; SOTALOL;

EID: 0036623832     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00040-5     Document Type: Review
Times cited : (66)

References (14)
  • 1
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Dahlof B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlof, B.1    Devereux, R.B.2    Kjeldsen, S.E.3
  • 2
    • 0037160969 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Lindholm LH, Ibsen H, Dahlof B, et al. for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
    • (2002) Lancet , vol.359 , pp. 1004-1010
    • Lindholm, L.H.1    Ibsen, H.2    Dahlof, B.3
  • 3
    • 0037149716 scopus 로고    scopus 로고
    • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction
    • Moss AJ, Zareba W, Hall J, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83.
    • (2002) N Engl J Med , vol.346 , Issue.12 , pp. 877-883
    • Moss, A.J.1    Zareba, W.2    Hall, J.3
  • 4
    • 0037149720 scopus 로고    scopus 로고
    • Expanding indications for implantable cardiac defibrillators
    • Bigger JT. Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002;346(12):931-3.
    • (2002) N Engl J Med , vol.346 , Issue.12 , pp. 931-933
    • Bigger, J.T.1
  • 6
    • 0037028893 scopus 로고    scopus 로고
    • Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%
    • Mar 6
    • Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol, Mar 6 2002;39(5):780-7.
    • (2002) J Am Coll Cardiol , vol.39 , Issue.5 , pp. 780-787
    • Grimm, W.1    Hoffmann, J.J.2    Muller, H.H.3    Maisch, B.4
  • 7
    • 0034831901 scopus 로고    scopus 로고
    • Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology 2001
    • Louis A, Cleland JGF, Crabbe S, Ford S, Thackray S, Houghton T, Clark A. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology 2001. Eur J Heart Fail 2001;3:381-7.
    • (2001) Eur J Heart Fail , vol.3 , pp. 381-387
    • Louis, A.1    Cleland, J.G.F.2    Crabbe, S.3    Ford, S.4    Thackray, S.5    Houghton, T.6    Clark, A.7
  • 8
    • 4244154167 scopus 로고    scopus 로고
    • Why ICD patients with heart failure (Class II-IV) are hospitalized: Do the reasons differ for patients who are treated with cardiac resynchronisation therapy?
    • Boehmer JP, DeMarco T, Jaski BE, Carlsen MD, Rathbun VL, Schmeichel CN. Why ICD patients with heart failure (Class II-IV) are hospitalized: Do the reasons differ for patients who are treated with cardiac resynchronisation therapy? JACC 2002;39:159A.
    • (2002) JACC , vol.39
    • Boehmer, J.P.1    DeMarco, T.2    Jaski, B.E.3    Carlsen, M.D.4    Rathbun, V.L.5    Schmeichel, C.N.6
  • 9
    • 0034888581 scopus 로고    scopus 로고
    • Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF
    • Thackray S, Coletta A, Jones P, Dunn A, Clark AL, Cleland JGF. Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail 2001;3:491-4.
    • (2001) Eur J Heart Fail , vol.3 , pp. 491-494
    • Thackray, S.1    Coletta, A.2    Jones, P.3    Dunn, A.4    Clark, A.L.5    Cleland, J.G.F.6
  • 10
    • 0033534085 scopus 로고    scopus 로고
    • Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
    • Packer M, Poole Wilson PA, Armstrong PW, et al. on behalf of the ATLAS investigators. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
    • (1999) Circulation , vol.100 , pp. 2312-2318
    • Packer, M.1    Poole Wilson, P.A.2    Armstrong, P.W.3
  • 11
    • 0033498214 scopus 로고    scopus 로고
    • The carvedilol hibernation reversible ischaemia trial: Marker of success (CHRISTMAS)
    • Cleland JGF, Pennell DJ, Ray S, et al. and The CHRISTMAS Study Steering Committee and Investigators, The Carvedilol Hibernation Reversible Ischaemia Trial: marker of success (CHRISTMAS). Eur J Heart Fail 1999;1:191-6.
    • (1999) Eur J Heart Fail , vol.1 , pp. 191-196
    • Cleland, J.G.F.1    Pennell, D.J.2    Ray, S.3
  • 13
    • 0034124255 scopus 로고    scopus 로고
    • Systematic review of the management of atrial fibrillation in patients with heart failure
    • Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000;21:614-32.
    • (2000) Eur Heart J , vol.21 , pp. 614-632
    • Khand, A.1    Rankin, A.C.2    Kaye, G.C.3    Cleland, J.G.F.4
  • 14
    • 0035892018 scopus 로고    scopus 로고
    • Long term use of a left ventricular assist device for end-stage heart failure
    • Rose EA, Gelijns AC, Moskowitz AJ, et al. for the randomised evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long term use of a left ventricular assist device for end-stage heart failure. N Eng J Med 2001;345:1435-43.
    • (2001) N Eng J Med , vol.345 , pp. 1435-1443
    • Rose, E.A.1    Gelijns, A.C.2    Moskowitz, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.